HeartBeam launches $15M public offering; reports positive trial results for portable 12-lead ECG

HeartBeam, Inc.

$15M public offering of common stock; proceeds for clinical/reg ($2M), R&D ($7M), sales/mkt ($1M), G&A ($5M).
HIDES study: VECG sensitivity 93%, specificity 95% vs cardiologist 70%/83% for early MI detection.
First 510(k) submission for recording device in Q1 2023; second for synthesized 12-lead in Q4 2023; clearances expected in 12 months.
Credit-card-sized device can replicate 12-lead ECG; holds foundational patents in portable VECG.
Management includes CEO Branislav Vajdic, CFO Rick Brounstein; advisor panel includes key cardiologists.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.